title: Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.
abstract: BACKGROUND
  The use of proton pump inhibitors for the treatment of functional dyspepsia is controversial and the role of Helicobacter pylori infection in functional dyspepsia is uncertain.
  
  
  OBJECTIVE
  To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients.
  
  
  METHODS
  Patients with a clinical diagnosis of functional dyspepsia according to the Rome II criteria and normal upper gastrointestinal endoscopy were recruited and randomised to receive: (1) lansoprazole 30 mg, (2) lansoprazole 15 mg, or (3) placebo, all given daily for four weeks. Dyspepsia symptom scores and quality of life (SF-36 score) were evaluated before and four weeks after treatment.
  
  
  RESULTS
  A total of 453 patients were randomised. There was no difference in the proportion of patients with complete symptom relief in the lansoprazole 30 mg (23%) and lansoprazole 15 mg (23%) groups compared with the placebo group (30%). The proportion of H pylori positive patients with a complete response was similar with lansoprazole 30 mg (34%) and lansoprazole 15 mg (20%) versus placebo (22%). All symptom subgroups (ulcer-like, dysmotility-like, reflux-like, and unspecified dyspepsia) had similar proportions of patients with complete symptom relief after treatment.
  
  
  CONCLUSIONS
  Proton pump inhibitor treatment is not superior to placebo for the management of functional dyspepsia in Chinese patients.
authors.affiliation: Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: W M
authors.initials: WM
authors.lastname: Wong
authors.forename: B C Y
authors.initials: BC
authors.lastname: Wong
authors.forename: W K
authors.initials: WK
authors.lastname: Hung
authors.forename: Y K
authors.initials: YK
authors.lastname: Yee
authors.forename: A W C
authors.initials: AW
authors.lastname: Yip
authors.forename: M L
authors.initials: ML
authors.lastname: Szeto
authors.forename: F M Y
authors.initials: FM
authors.lastname: Fung
authors.forename: T S M
authors.initials: TS
authors.lastname: Tong
authors.forename: K C
authors.initials: KC
authors.lastname: Lai
authors.forename: W H C
authors.initials: WH
authors.lastname: Hu
authors.forename: M F
authors.initials: MF
authors.lastname: Yuen
authors.forename: S K
authors.initials: SK
authors.lastname: Lam
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002681:China; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole